Ser277
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser277  -  CREM (human)

Site Information
AsPGsLHsPQQLAEE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 450066

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 11 ) , mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 ) , mass spectrometry (in vitro) ( 4 ) , mutation of modification site ( 4 , 11 ) , phosphoamino acid analysis ( 4 ) , western blotting ( 11 )
Disease tissue studied:
gestational cancer ( 11 ) , gestational trophoblastic choriocarcinoma ( 11 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 ) , pituitary cancer ( 11 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 4 ) , ERK1 (human) ( 11 )
Kinases, in vitro:
CDK1 (human) ( 4 )
Treatments:
EGF ( 11 ) , seliciclib ( 4 )

Downstream Regulation
Effects of modification on CREM:
protein degradation ( 11 ) , ubiquitination ( 11 )

References 

1

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

2

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

3

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

4

Mémin E, Genzale M, Crow M, Molina CA (2011) Evidence that phosphorylation by the mitotic kinase Cdk1 promotes ICER monoubiquitination and nuclear delocalization. Exp Cell Res 317, 2490-502
21767532   Curated Info

5

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

6

Zhou J (2010) CST Curation Set: 10709; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

7

Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13
19664994   Curated Info

8

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

9

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

10

Cantin GT, et al. (2008) Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res 7, 1346-51
18220336   Curated Info

11

Yehia G, et al. (2001) Mitogen-activated protein kinase phosphorylates and targets inducible cAMP early repressor to ubiquitin-mediated destruction. J Biol Chem 276, 35272-9
11466319   Curated Info